LEADER 02365nam  2200565 a 450 
001 9910877723203321
005 20200520144314.0
010   $a1-283-17566-5
010   $a9786613175663
010   $a1-118-02366-8
010   $a1-118-02367-6
010   $a1-118-02365-X
035   $a(CKB)2550000000041121
035   $a(EBL)693249
035   $a(OCoLC)745970855
035   $a(SSID)ssj0000524794
035   $a(PQKBManifestationID)12222185
035   $a(PQKBTitleCode)TC0000524794
035   $a(PQKBWorkID)10488185
035   $a(PQKB)11413967
035   $a(MiAaPQ)EBC693249
035   $a(PPN)243334850
035   $a(EXLCZ)992550000000041121
100   $a20101020d2011      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aPharmaceutical anti-counterfeiting $ecombating the real danger from fake drugs /$fMark Davison
210   $aHoboken, N.J. $cJohn Wiley & Sons$dc2011
215   $a1 online resource (428 p.)
300   $aDescription based upon print version of record.
311   $a0-470-61617-2 
320   $aIncludes bibliographical references and index.
327   $apt. 1. General themes -- pt. 2. Authentication -- pt. 3. Product tracking -- pt. 4. Conclusions and the future -- pt. 5. Further Resources.
330   $aThis book overviews and integrates the business and technical issues that pharmaceutical companies need to know in order to combat the major global problem of counterfeit medicines. In addition to discussion of the problems, the author Davison addresses analytical techniques scientists use to detect counterfeits and presents some possible solutions to the threat of counterfeit medical products. Coverage moves from basic overview of the problem, costs / risks to consumers (toxic products, mistrust of drug companies) and business (revenue loss, public trust), government oversight and regulation,
606   $aProduct counterfeiting
606   $aDrug adulteration
615  0$aProduct counterfeiting.
615  0$aDrug adulteration.
676   $a615.1068/4
700   $aDavison$b Mark$f1968 Mar. 1-$01761835
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910877723203321
996   $aPharmaceutical anti-counterfeiting$94201491
997   $aUNINA